Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension

被引：16

作者：

Sanidas, Elias A. ^{[1
]}

Papadopoulos, Dimitrios P. ^{[1
]}

Hatziagelaki, Erifili ^{[2
]}

Grassos, Charalampos ^{[3
]}

Velliou, Maria ^{[1
]}

Barbetseas, John ^{[1
]}

机构：

[1] Laikon Gen Hosp, Dept Cardiol, Hypertens Excellence Ctr ESH, Athens, Greece

[2] Athens Med Sch, Attikon Gen Hosp, Dept Internal Med 2, Athens, Greece

[3] KAT Gen Hosp, Hypertens Excellence Ctr ESH, Dept Cardiol, Athens, Greece

来源：

AMERICAN JOURNAL OF HYPERTENSION | 2020年 / 33卷 / 03期

关键词：

arterial hypertension; blood pressure; diabetes mellitus; SGLT-2; Inhibitors; TYPE-2; DIABETES-MELLITUS; BLOOD-PRESSURE; EMPAGLIFLOZIN; DAPAGLIFLOZIN; CANAGLIFLOZIN; REDUCTION; SAFETY; IMPACT; RHYTHM;

D O I：

10.1093/ajh/hpz157

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Sodium glucose cotransporter 2 (SGLT2) inhibitors represent a novel class of oral antihyperglycemic drugs that have been approved over the last decade for the management of type 2 diabetes mellitus. Except the glucose-lowering effects, robust evidence also suggests that SGLT2 inhibitors confer benefits in cardiovascular system. The purpose of this review was to investigate the effects of SGLT2 inhibitors across the spectrum of arterial hypertension.

引用

页码：207 / 213

页数：7

共 37 条

[21] Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes [J].

Neal, Bruce ;

Perkovic, Vlado ;

Mahaffey, Kenneth W. ;

de Zeeuw, Dick ;

Fulcher, Greg ;

Erondu, Ngozi ;

Shaw, Wayne ;

Law, Gordon ;

Desai, Mehul ;

Matthews, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (07) :644-657

[22] Hypertension with diabetes mellitus: physiology and pathology [J].

Ohishi, Mitsuru .

HYPERTENSION RESEARCH, 2018, 41 (06) :389-393

[23] Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure [J].

Reed, James W. .

VASCULAR HEALTH AND RISK MANAGEMENT, 2016, 12 :393-405

[24] An update on the safety of SGLT2 inhibitors [J].

Scheen, Andre J. .

EXPERT OPINION ON DRUG SAFETY, 2019, 18 (04) :295-311

[25] Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes [J].

Sjostrom, C. David ;

Johansson, Peter ;

Ptaszynska, Agata ;

List, James ;

Johnsson, Eva .

DIABETES & VASCULAR DISEASE RESEARCH, 2015, 12 (05) :352-358

[26] A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats [J].

Takeshige, Yui ;

Fujisawa, Yoshihide ;

Rahman, Asadur ;

Kittikulsuth, Wararat ;

Nakano, Daisuke ;

Mori, Hirohito ;

Masaki, Tsutomu ;

Ohmori, Koji ;

Kohno, Masakazu ;

Ogata, Hiroaki ;

Nishiyama, Akira .

HYPERTENSION RESEARCH, 2016, 39 (06) :415-422

[27] Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes [J].

Tamura, Kouichi ;

Wakui, Hiromichi ;

Azushima, Kengo ;

Uneda, Kazushi ;

Umemura, Satoshi .

HYPERTENSION RESEARCH, 2016, 39 (06) :396-398

[28] Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension [J].

Tikkanen, Ilkka ;

Narko, Kirsi ;

Zeller, Cordula ;

Green, Alexandra ;

Salsali, Afshin ;

Broedl, Uli C. ;

Woerle, Hans J. .

DIABETES CARE, 2015, 38 (03) :420-428

[29] Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension [J].

Townsend, Raymond R. ;

Machin, Israel ;

Ren, Jimmy ;

Trujillo, Angelina ;

Kawaguchi, Masato ;

Vijapurkar, Ujjwala ;

Damaraju, Chandrasekharrao V. ;

Pfeifer, Michael .

JOURNAL OF CLINICAL HYPERTENSION, 2016, 18 (01) :43-52

[30] Sodium-glucose transport: role in diabetes mellitus and potential clinical implications [J].

Vallon, Volker ;

Sharma, Kumar .

CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2010, 19 (05) :425-431

← 1 2 3 4 →